Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

Friend or foe-IDH1 mutations in glioma 10 years on.

Huang LE.

Carcinogenesis. 2019 Sep 3. pii: bgz134. doi: 10.1093/carcin/bgz134. [Epub ahead of print]

PMID:
31504231
2.

IDH1R132H is intrinsically tumor-suppressive but functionally attenuated by the glutamate-rich cerebral environment.

Tiburcio PDB, Xiao B, Chai Y, Asper S, Tripp SR, Gillespie DL, Jensen RL, Huang LE.

Oncotarget. 2018 Oct 12;9(80):35100-35113. doi: 10.18632/oncotarget.26203. eCollection 2018 Oct 12.

3.

Diagnostic value of glutamate with 2-hydroxyglutarate in magnetic resonance spectroscopy for IDH1 mutant glioma.

Nagashima H, Tanaka K, Sasayama T, Irino Y, Sato N, Takeuchi Y, Kyotani K, Mukasa A, Mizukawa K, Sakata J, Yamamoto Y, Hosoda K, Itoh T, Sasaki R, Kohmura E.

Neuro Oncol. 2016 Nov;18(11):1559-1568. Epub 2016 May 5.

4.

From genomics to the clinic: biological and translational insights of mutant IDH1/2 in glioma.

Dunn GP, Andronesi OC, Cahill DP.

Neurosurg Focus. 2013 Feb;34(2):E2. doi: 10.3171/2012.12.FOCUS12355. Review.

PMID:
23373447
5.

Adaptive Evolution of the GDH2 Allosteric Domain Promotes Gliomagenesis by Resolving IDH1R132H-Induced Metabolic Liabilities.

Waitkus MS, Pirozzi CJ, Moure CJ, Diplas BH, Hansen LJ, Carpenter AB, Yang R, Wang Z, Ingram BO, Karoly ED, Mohney RP, Spasojevic I, McLendon RE, Friedman HS, He Y, Bigner DD, Yan H.

Cancer Res. 2018 Jan 1;78(1):36-50. doi: 10.1158/0008-5472.CAN-17-1352. Epub 2017 Nov 2.

6.

IDH1/2 mutations target a key hallmark of cancer by deregulating cellular metabolism in glioma.

Zhang C, Moore LM, Li X, Yung WK, Zhang W.

Neuro Oncol. 2013 Sep;15(9):1114-26. doi: 10.1093/neuonc/not087. Epub 2013 Jul 21. Review.

7.

In silico gene expression analysis reveals glycolysis and acetate anaplerosis in IDH1 wild-type glioma and lactate and glutamate anaplerosis in IDH1-mutated glioma.

Khurshed M, Molenaar RJ, Lenting K, Leenders WP, van Noorden CJF.

Oncotarget. 2017 Jul 25;8(30):49165-49177. doi: 10.18632/oncotarget.17106.

8.

Isocitrate dehydrogenase mutations in gliomas.

Waitkus MS, Diplas BH, Yan H.

Neuro Oncol. 2016 Jan;18(1):16-26. doi: 10.1093/neuonc/nov136. Epub 2015 Jul 16. Review.

9.

Mutant IDH1 and thrombosis in gliomas.

Unruh D, Schwarze SR, Khoury L, Thomas C, Wu M, Chen L, Chen R, Liu Y, Schwartz MA, Amidei C, Kumthekar P, Benjamin CG, Song K, Dawson C, Rispoli JM, Fatterpekar G, Golfinos JG, Kondziolka D, Karajannis M, Pacione D, Zagzag D, McIntyre T, Snuderl M, Horbinski C.

Acta Neuropathol. 2016 Dec;132(6):917-930. Epub 2016 Sep 23.

10.

2-hydroxyglutarate production, but not dominant negative function, is conferred by glioma-derived NADP-dependent isocitrate dehydrogenase mutations.

Jin G, Reitman ZJ, Spasojevic I, Batinic-Haberle I, Yang J, Schmidt-Kittler O, Bigner DD, Yan H.

PLoS One. 2011 Feb 4;6(2):e16812. doi: 10.1371/journal.pone.0016812.

11.

IDH1 and IDH2 mutations as novel therapeutic targets: current perspectives.

Mondesir J, Willekens C, Touat M, de Botton S.

J Blood Med. 2016 Sep 2;7:171-80. doi: 10.2147/JBM.S70716. eCollection 2016. Review.

12.

Hyperpolarized (13)C MR imaging detects no lactate production in mutant IDH1 gliomas: Implications for diagnosis and response monitoring.

Chaumeil MM, Radoul M, Najac C, Eriksson P, Viswanath P, Blough MD, Chesnelong C, Luchman HA, Cairncross JG, Ronen SM.

Neuroimage Clin. 2016 Jun 23;12:180-9. doi: 10.1016/j.nicl.2016.06.018. eCollection 2016.

13.

Molecular mechanisms of isocitrate dehydrogenase 1 (IDH1) mutations identified in tumors: The role of size and hydrophobicity at residue 132 on catalytic efficiency.

Avellaneda Matteo D, Grunseth AJ, Gonzalez ER, Anselmo SL, Kennedy MA, Moman P, Scott DA, Hoang A, Sohl CD.

J Biol Chem. 2017 May 12;292(19):7971-7983. doi: 10.1074/jbc.M117.776179. Epub 2017 Mar 22.

14.

Metabolic reprogramming in mutant IDH1 glioma cells.

Izquierdo-Garcia JL, Viswanath P, Eriksson P, Chaumeil MM, Pieper RO, Phillips JJ, Ronen SM.

PLoS One. 2015 Feb 23;10(2):e0118781. doi: 10.1371/journal.pone.0118781. eCollection 2015.

15.

Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations.

Gross S, Cairns RA, Minden MD, Driggers EM, Bittinger MA, Jang HG, Sasaki M, Jin S, Schenkein DP, Su SM, Dang L, Fantin VR, Mak TW.

J Exp Med. 2010 Feb 15;207(2):339-44. doi: 10.1084/jem.20092506. Epub 2010 Feb 8.

16.

The comparison of clinical and biological characteristics between IDH1 and IDH2 mutations in gliomas.

Wang HY, Tang K, Liang TY, Zhang WZ, Li JY, Wang W, Hu HM, Li MY, Wang HQ, He XZ, Zhu ZY, Liu YW, Zhang SZ.

J Exp Clin Cancer Res. 2016 May 31;35:86. doi: 10.1186/s13046-016-0362-7.

17.

Consequences of IDH1/2 Mutations in Gliomas and an Assessment of Inhibitors Targeting Mutated IDH Proteins.

Kaminska B, Czapski B, Guzik R, Król SK, Gielniewski B.

Molecules. 2019 Mar 9;24(5). pii: E968. doi: 10.3390/molecules24050968. Review.

18.

Development of Novel Therapeutics Targeting Isocitrate Dehydrogenase Mutations in Cancer.

Sharma H.

Curr Top Med Chem. 2018;18(6):505-524. doi: 10.2174/1568026618666180518091144. Review.

PMID:
29773061
19.

Isocitrate Dehydrogenase Mutations are Better Prognostic Marker than O6-methylguanine-DNA Methyltransferase Promoter Methylation in Glioblastomas - a Retrospective, Single-centre Molecular Genetics Study of Gliomas.

Houdova Megova M, Drábek J, Dwight Z, Trojanec R, Koudeláková V, Vrbková J, Kalita O, Mlcochova S, Rabcanova M, Hajdúch M.

Klin Onkol. Fall 2017;30(5):361-371. doi: 10.14735/amko2017361.

PMID:
29031038
20.

Tumor-suppressive miR148a is silenced by CpG island hypermethylation in IDH1-mutant gliomas.

Li S, Chowdhury R, Liu F, Chou AP, Li T, Mody RR, Lou JJ, Chen W, Reiss J, Soto H, Prins R, Liau LM, Mischel PS, Nghiemphu PL, Yong WH, Cloughesy TF, Lai A.

Clin Cancer Res. 2014 Nov 15;20(22):5808-22. doi: 10.1158/1078-0432.CCR-14-0234. Epub 2014 Sep 15.

Supplemental Content

Support Center